aldeyra.com (ALDX) Amount of Cash per Share

Symbol and logo of brand Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics (ALDX) utilizes a unique aldehyde scavenger technology that enables steroid-free eye treatment, a position supported by the company's cash per share. The value 0.69 serves as the current liquidity parameter. While revenue growth relies on the market launch of reproxalap, potential FDA delays and uncertainty regarding partnerships with pharma behemoths are creating downward pressure on the stock.

aldeyra.com (ALDX): Cash per Single Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for aldeyra.com (ALDX)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:ALDX (Aldeyra Therapeutics Inc.)
Finished products of Aldeyra Therapeutics

For the US ophthalmology biotech sector, which remains shielded from geopolitical shocks, liquidity reserves serve as a guarantee of operational stability during drug development. The cash per share history reflects the actual volume of cash reserves attributable to a single security, allowing investors to assess the real cash cushion of Aldeyra Therapeutics (ALDX) relative to its market value.